• In May 2026, Immunovant, Inc. reported a wider quarterly and full-year net loss, with fourth-quarter net loss rising to US$147.86 million and full-year net loss to US$505.61 million, while maintaining a cash balance above US$900 million and recording no revenue.
• At the same time, Immunovant released encouraging Week 16 data for its lead FcRn inhibitor IMVT-1402 in difficult-to-treat rheumatoid arthritis and discontinued batoclimab after Phase 3 failures, signaling a concentrated push behind one core autoimmune asset.
• With IMVT-1402 now the clear focal point after batoclimab’s discontinuation, we’ll examine how this shifts Immunovant’s investment narrative.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

Immunovant Investment Narrative Recap

To own Immunovant, you need to believe IMVT-1402 can convert strong mid‑stage autoimmune data into successful late‑stage trials and, eventually, a commercial product, despite today’s zero revenue and widening losses. The recent Week 16 rheumatoid arthritis data strengthen the near term clinical catalyst, while the discontinuation of batoclimab concentrates risk in a single asset and keeps trial execution and class competition as the key near term swing factors.

The May 2026 earnings release, showing a larger full year net loss of US$505.61 million but more than US$900 million in cash, is central to this story. It underlines that Immunovant is still in heavy investment mode yet appears funded through key IMVT-1402 milestones in Graves’ disease and other indications, which matters for how much financing and dilution might be needed around those catalysts.

Yet, despite the enthusiasm around IMVT-1402, investors should be aware that...

Immunovant's narrative projects $381.4 million revenue and $47.7 million earnings by 2029. This requires an earnings increase of about $512 million from -$464.2 million today.

Uncover how Immunovant's forecasts yield a $41.12 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling around US$520.0 million of revenue and roughly US$56.6 million of earnings by 2029, which is a far rosier path than the consensus view. With the new IMVT-1402 data and batoclimab’s exit, you now have to decide whether that bullish scenario feels more realistic or further out of reach, and that is where understanding the full spread of opinions really matters.

Explore 2 other fair value estimates on Immunovant - why the stock might be worth as much as 29% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunovant research is our analysis highlighting 5 important warning signs that could impact your investment decision.
• Our free Immunovant research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunovant's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.